HealthQuill Pharma
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.
Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four cases of neurovascular events related to the device.
Health Medical Pharma

J&J pauses rollout of heart device in US after ischemic, stroke incidents

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.

Read More
China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news agency.
Health Medical Pharma

China to make humanoid robots, brain-computer interfaces for elderly

China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news.

Read More
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More
US-based medical device maker Stryker Corporation will acquire Inari Medical Inc., for about $4.9 billion to expand the former’s neurovascular business.
Drugs Medical Pharma

Stryker to buy Inari for $4.9b to expand neurovascular business

US-based medical device maker Stryker Corporation will acquire Inari Medical Inc., for about $4.9 billion to expand the former’s neurovascular business.

Read More
Maternal deaths have risen or stagnated globally over recent years, and every two minutes, a woman dies during pregnancy or childbirth, according to the WHO.
Drugs Pharma Research

Study links gestational NSAID use to risk of childhood chronic kidney disease

HQ Team December 28, 2024: A study from Taiwan links the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy, with a potential risk.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s damaged blood vessel after a traumatic injury.
Drugs Health Medical Pharma

Humacyte’s tissue-engineered blood vessel for vascular trauma gets nod

Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.

Read More